VANCOUVER, BC, June 1, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND)(“MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce the expansion of our intellectual property portfolio to more precisely diagnose and then monitor the treatment regime for patients with Major Depressive Disorder (MDD)…


Previous articleHorizons ETFs Announces Methodology Update for the North American Psychedelics Index
Next articlePT246 – Amber and Marcus Capone of VETS – Foundational Healing and the Brain